Otsuka Pharmaceutical Co., Ltd. Release: Results from a Phase 3 Study of Once-Monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at American Psychiatric Association Annual Meeting

PHILADELPHIA--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerab…
Read the full story: BioSpace.com Featured News